MI
CRDF icon

Motiv8 Investments’s Cardiff Oncology CRDF Stock Holding History

Motiv8 Investments’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1 Buy
+200
New +$464 ﹤0.01% 828

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Motiv8 Investments's CRDF Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Cardiff Oncology (CRDF) in Q4 2025: 200 shares worth $1. The stake represents ﹤0.01% of the portfolio and ranks #828 among its holdings.

110 funds tracked by Wall St. Rank hold CRDF as of Q4 2025.

  • Motiv8 Investments held 200 shares of Cardiff Oncology worth $1 as of Q4 2025.
  • Cardiff Oncology was a new Motiv8 Investments position in Q4 2025.
  • Cardiff Oncology made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #828 holding.
  • 110 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.